Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias.
Endlyz Therapeutics has raised $17.3M in total funding. The most recent round was Seed. The last funding was announced in April 2026.
Endlyz Therapeutics's investors include AbbVie, Oxford Science Enterprises, Dementia Discovery Fund, Michael J. Fox Foundation, Centre for Drug Design & Discovery (CD3).
Endlyz Therapeutics is headquartered in Boston, United States.
Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias.
Endlyz Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endlyz Therapeutics — Funding & Investors." VCBacked, April 23, 2026, https://www.vcbacked.co/company/endlyz-therapeutics. Accessed October 1, 2026.
VCBacked. (2026). Endlyz Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/endlyz-therapeutics
{{cite web |title=Endlyz Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/endlyz-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated